Company Description
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.
It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease.
The company’s pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701.
It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis.
MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
| Country | United States |
| Founded | 1991 |
| IPO Date | Jul 28, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 407 |
| CEO | Michael Castagna |
Contact Details
Address: 1 Casper Street Danbury, Connecticut 06810 United States | |
| Phone | 818 661 5000 |
| Website | mannkindcorp.com |
Stock Details
| Ticker Symbol | MNKD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000899460 |
| CUSIP Number | 56400P706 |
| ISIN Number | US56400P7069 |
| Employer ID | 13-3607736 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael E. Castagna Pharm.D. | Chief Executive Officer and Director |
| Christopher B. Prentiss M.B.A. | Chief Financial Officer |
| Dr. David B. Thomson J.D., Ph.D. | Executive Vice President, General Counsel and Secretary |
| Sanjay Singh M.B.A. | Executive Vice President of Technical Operations |
| Dr. Stuart A. Tross Ph.D. | Chief People and Workplace Officer |
| Dominic Marasco R.Ph. | President of Endocrine Business Unit |
| Dr. Ajay Ahuja M.B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 8, 2026 | 144 | Filing |
| Dec 15, 2025 | 8-K/A | [Amend] Current report |
| Dec 12, 2025 | 144 | Filing |
| Dec 2, 2025 | 144 | Filing |
| Dec 2, 2025 | 144 | Filing |
| Nov 14, 2025 | 144 | Filing |
| Nov 10, 2025 | 8-K | Current Report |
| Nov 5, 2025 | 10-Q | Quarterly Report |
| Nov 5, 2025 | 8-K | Current Report |
| Oct 9, 2025 | 8-K | Current Report |